Baxter International Inc
NYSE:BAX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
31.7
43.77
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Baxter International Inc
Baxter International Inc
Capital Expenditures
Baxter International Inc
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Baxter International Inc
NYSE:BAX
|
Capital Expenditures
-$656m
|
CAGR 3-Years
4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
5%
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Capital Expenditures
-$725m
|
CAGR 3-Years
15%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-1%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Capital Expenditures
-$780m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-10%
|
|
|
Stryker Corp
NYSE:SYK
|
Capital Expenditures
-$634m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-11%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Capital Expenditures
-$2.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-7%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Capital Expenditures
-$1.2B
|
CAGR 3-Years
-67%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-33%
|
|
Baxter International Inc
Glance View
Baxter International Inc. is a global healthcare company that has been a trusted name in the medical sector for over eight decades. Founded in 1931, Baxter specializes in lifesaving medical products and therapies, primarily focusing on renal and hospital care. The company's innovations have revolutionized treatment protocols for conditions such as kidney failure, where their dialysis products are vital for patient care. Additionally, Baxter manufactures a diverse range of infusion systems, biosurgery products, and medications, playing a crucial role in surgical and medical environments. With a commitment to improving patient outcomes, Baxter invests heavily in research and development, which positions it well for future growth, particularly as global healthcare needs continue to expand. As an investor, understanding Baxter’s strategic position in the healthcare industry is key. The company enjoys a robust financial footing, bolstered by its extensive product portfolio and a global distribution network that spans over 100 countries. Recently, Baxter has focused on enhancing its operational efficiency and pursuing strategic acquisitions to broaden its product offerings and enter emerging markets. Moreover, as healthcare systems worldwide prioritize chronic disease management, Baxter’s innovative solutions are increasingly in demand, reinforcing its potential for sustainable revenue growth. In an ever-evolving healthcare landscape, Baxter International Inc. stands out as a formidable player, driven by a mission to save and sustain lives, making it an attractive option for long-term investors looking to enter the healthcare sector.
See Also
What is Baxter International Inc's Capital Expenditures?
Capital Expenditures
-656m
USD
Based on the financial report for Sep 30, 2024, Baxter International Inc's Capital Expenditures amounts to -656m USD.
What is Baxter International Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
5%
Over the last year, the Capital Expenditures growth was 7%. The average annual Capital Expenditures growth rates for Baxter International Inc have been 4% over the past three years , 2% over the past five years , and 5% over the past ten years .
You don't have any saved screeners yet
